Stile Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 13.58%
(FY 2020)
- Profit 285.54%
(FY 2020)
- Ebitda 451.55%
(FY 2020)
- Net Worth 23.14%
(FY 2020)
- Total Assets -25.16%
(FY 2020)
About Stile Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Padhma Philcheli and Harish Kandpal serve as directors at the Company.
- CIN/LLPIN
U24297MH2014PTC257973
- Company No.
257973
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Stile Pharmaceuticals Private Limited offer?
Stile Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Protein Powder, Mineral Supplement, Calcium Tablet, Calcium Citrate and Vitamin D3 Tablet, Fitness Supplements, Coenzyme Q10 Tablets and Capsules, Vitamin Tablets & Capsules, Methylcobalamin Tablets, Multivitamin Tablets & Capsules.
Who are the key members and board of directors at Stile Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padhma Philcheli  | Director | 10-Sep-2014 | Current |
| Harish Kandpal | Director | 10-Sep-2014 | Current |
Financial Performance of Stile Pharmaceuticals.
Stile Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.58% increase. The company also saw a substantial improvement in profitability, with a 285.54% increase in profit. The company's net worth Soared by an impressive increase of 23.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stile Pharmaceuticals?
In 2020, Stile Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stile Pharmaceuticals?
Unlock and access historical data on people associated with Stile Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stile Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stile Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
